Chinese Authorities Issued Operating Approval To Siegfried Nantong
The Chinese Environmental Protection Bureau (EPB) has issued Siegfried Group (SIX: SFZN) the final operating approval for its Nantong production site. Consequently, all approvals and certificates required by the authorities for large-scale production have now been obtained. Trial operation for the commercial facilities already started a year ago.
Siegfried’s Nantong production site is located in one of China’s most up-to-date industrial parks northwest of Shanghai. The site’s production capacity amounts to 350 cubic meters and provides work for about 200 employees. This significant site addition to Siegfried’s production network in a cost-effective production environment strengthens the company’s long-term competitiveness. The facility was inaugurated in August 2015 and is attracting a great deal of interest from customers.
Dr. Walter Kittl, Head Global Operations at Siegfried: „Thanks to the final operation approval of the Chinese Environmental Protection Bureau our production network and thus our customers can now profit from a modern multi-purpose plant, complying with highest safety, environmental and quality standards”.
The pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2015, Siegfried reported annual sales of CHF 481 million and employs at the time being approximately 2200 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
Siegfried’s Nantong production site is located in one of China’s most up-to-date industrial parks northwest of Shanghai. The site’s production capacity amounts to 350 cubic meters and provides work for about 200 employees. This significant site addition to Siegfried’s production network in a cost-effective production environment strengthens the company’s long-term competitiveness. The facility was inaugurated in August 2015 and is attracting a great deal of interest from customers.
Dr. Walter Kittl, Head Global Operations at Siegfried: „Thanks to the final operation approval of the Chinese Environmental Protection Bureau our production network and thus our customers can now profit from a modern multi-purpose plant, complying with highest safety, environmental and quality standards”.
The pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2015, Siegfried reported annual sales of CHF 481 million and employs at the time being approximately 2200 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.